Neoadjuvant treatments for triple-negative breast cancer (TNBC)
ANNALS OF ONCOLOGY (2012)
期刊
ANNALS OF ONCOLOGY
卷 23, 期 -, 页码 35-39出版社
OXFORD UNIV PRESS
关键词
类别
资金
- Sanofi
作者
我是这篇论文的作者
推荐
Transcriptome Meta-Analysis of Triple-Negative Breast Cancer Response to Neoadjuvant Chemotherapy
Wei Zhang, Emma Li, Lily Wang, Brian D. D. Lehmann, X. Steven Chen
CANCERS (2023)
Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer
Cornelia Liedtke, Chafika Mazouni, Kenneth R. Hess, Fabrice Andre, Attila Tordai, Jaime A. Mejia, W. Fraser Symmans, Ana M. Gonzalez-Angulo, Bryan Hennessy, Marjorie Green, Massimo Cristofanilli, Gabriel N. Hortobagyi, Lajos Pusztai
JOURNAL OF CLINICAL ONCOLOGY (2023)
Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer
Clinton Yam, Er-Yen Yen, Jeffrey T. Chang, Roland L. Bassett, Gheath Alatrash, Haven Garber, Lei Huo, Fei Yang, Anne Philips, Qing-Qing Ding, Bora Lim, Naoto T. Ueno, Kasthuri Kannan, Xiangjie Sun, Baohua Sun, Edwin Roger Parra Cuentas, William Fraser Symmans, Jason B. White, Elizabeth Ravenberg, Sahil Seth, Jennifer L. Guerriero, Gaiane M. Rauch, Senthil Damodaran, Jennifer K. Litton, Jennifer A. Wargo, Gabriel N. Hortobagyi, Andrew Futreal, Ignacio I. Wistuba, Ryan Sun, Stacy L. Moulder, Elizabeth A. Mittendorf
CLINICAL CANCER RESEARCH (2021)
The Landmark Series: Neoadjuvant Chemotherapy for Triple-Negative and HER2-Positive Breast Cancer
Roberto A. Leon-Ferre, Tina J. Hieken, Judy C. Boughey
ANNALS OF SURGICAL ONCOLOGY (2021)
Time to Optimize Deescalation Strategies in Triple-Negative Breast Cancer?
Priyanka Sharma
CLINICAL CANCER RESEARCH (2022)
Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response
S. Loibl, A. Schneeweiss, J. Huober, M. Braun, J. Rey, J. U. Blohmer, J. Furlanetto, D. M. Zahm, C. Hanusch, J. Thomalla, C. Jackisch, P. Staib, T. Link, K. Rhiem, C. Solbach, P. A. Fasching, V. Nekljudova, C. Denkert, M. Untch
ANNALS OF ONCOLOGY (2022)
Nanoparticles for Chemoimmunotherapy Against Triple-Negative Breast Cancer
Siyan Liu, Jing Li, Lin Gu, Kunzhe Wu, Hua Xing
INTERNATIONAL JOURNAL OF NANOMEDICINE (2022)
Platinum and Taxane Based Adjuvant and Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: A Narrative Review
Hao Tian, Dandan Ma, Xuanni Tan, Wenting Yan, Xiujuan Wu, Cheng He, Ling Zhong, Yan Zhang, Bingjie Yu, Yi Zhang, Xiaowei Qi
FRONTIERS IN PHARMACOLOGY (2021)
A Nomogram to Predict Disease-Free Survival Following Neoadjuvant Chemotherapy for Triple Negative Breast Cancer
Meizhen Zhu, Chenlu Liang, Fanrong Zhang, Liang Zhu, Daobao Chen
FRONTIERS IN ONCOLOGY (2021)
Updates in Neoadjuvant Therapy for Triple Negative Breast Cancer
Andrea M. Tufano, Eleonora Teplinsky, Chrystal A. Landry
CLINICAL BREAST CANCER (2021)
Exosomal miRNA profiles of triple-negative breast cancer in neoadjuvant treatment
Aiko Sueta, Yoshitaka Fujiki, Lisa Goto-Yamaguchi, Mai Tomiguchi, Mutsuko Yamamoto-Ibusuki, Hirotaka Iwase, Yutaka Yamamoto
ONCOLOGY LETTERS (2021)
Multiomics technologies for comprehensive tumor microenvironment analysis in triple-negative breast cancer under neoadjuvant chemotherapy
Gang Wang, Yao Yao, Huanhuan Huang, Jun Zhou, Chao Ni
FRONTIERS IN ONCOLOGY (2023)
One therapeutic approach for triple-negative breast cancer: Checkpoint kinase 1 inhibitor AZD7762 combination with neoadjuvant carboplatin
Haiying Zhu, Zijian Rao, Sichen Yuan, Jieqiong You, Chenggang Hong, Qiaojun He, Bo Yang, Chengyong Du, Ji Cao
EUROPEAN JOURNAL OF PHARMACOLOGY (2021)
High expression of MORC2 predicts worse neoadjuvant chemotherapy efficacy in triple negative breast cancer
Xiaohong Liao, Chao Liu, Zhenluo Ding, Chen Wang, Jing He, Shugui Wu
MEDICINE (2023)
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer
P. Schmid, J. Cortes, R. Dent, L. Pusztai, H. McArthur, S. Kummel, J. Bergh, C. Denkert, Y. H. Park, R. Hui, N. Harbeck, M. Takahashi, M. Untch, P. A. Fasching, F. Cardoso, J. Andersen, D. Patt, M. Danso, M. Ferreira, M-A Mouret-Reynier, S-A Im, J-H Ahn, M. Gion, S. Baron-Hay, J-F Boileau, Y. Ding, K. Tryfonidis, G. Aktan, V Karantza, J. O'Shaughnessy
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial
Arlene Chan, Beverly Moy, Janine Mansi, Bent Ejlertsen, Frankie Ann Holmes, Stephen Chia, Hiroji Iwata, Michael Gnant, Sibylle Loibl, Carlos H. Barrios, Isil Somali, Snezhana Smichkoska, Noelia Martinez, Mirta Garcia Alonso, John S. Link, Ingrid A. Mayer, Soren Cold, Serafin Morales Murillo, Francis Senecal, Kenichi Inoue, Manuel Ruiz-Borrego, Rina Hui, Neelima Denduluri, Debra Patt, Hope S. Rugo, Stephen R. D. Johnston, Richard Bryce, Bo Zhang, Feng Xu, Alvin Wong, Miguel Martin
CLINICAL BREAST CANCER (2021)
At the bedside: Profiling and treating patients with CXCR4-expressing cancers
Miguel Martin, Ingrid A. Mayer, Annemiek M. E. Walenkamp, Constantin Lapa, Michael Andreeff, Alexandra Bobirca
JOURNAL OF LEUKOCYTE BIOLOGY (2021)
Aggressiveness of end-of-life cancer care: what happens in clinical practice?
Estela Garcia-Martin, Vicente Escudero-Vilaplana, Barbara Fox, Roberto Collado-Borrell, Belen Marzal-Alfaro, Maria Sanchez-Isac, Maria Luisa Solano-Garzon, Ricardo Gonzalez del Val, Jose Manuel Cano-Gonzalez, Nuria Perez de Lucas, Ana Isabel Bravo-Guillen, Javier Valero-Salinas, Eva Gonzalez-Haba, Maria Sanjurjo, Miguel Martin
SUPPORTIVE CARE IN CANCER (2021)
Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial-PEARL
M. Martin, C. Zielinski, M. Ruiz-Borrego, E. Carrasco, N. Turner, E. M. Ciruelos, M. Munoz, B. Bermejo, M. Margeli, A. Anton, Z. Kahan, T. Csoszi, M. Casas, L. Murillo, S. Morales, E. Alba, E. Gal-Yam, A. Guerrero-Zotano, L. Calvo, J. de la Haba-Rodriguez, M. Ramos, I Alvarez, A. Garcia-Palomo, C. Huang Bartlett, M. Koehler, R. Caballero, M. Corsaro, X. Huang, J. A. Garcia-Saenz, J. Chacon, C. Swift, C. Thallinger, M. Gil-Gil
ANNALS OF ONCOLOGY (2021)
Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer
Francesco Schettini, Mario Giuliano, Matteo Lambertini, Rupert Bartsch, David James Pinato, Concetta Elisa Onesti, Nadia Harbeck, Diana Lueftner, Sylvie Rottey, Peter A. van Dam, Khalil Zaman, Giorgio Mustacchi, Joseph Gligorov, Ahmad Awada, Mario Campone, Hans Wildiers, Alessandra Gennari, Vivianne C. G. Tjan-Heijnen, Javier Cortes, Mariavittoria Locci, Ida Paris, Lucia Del Mastro, Sabino De Placido, Miguel Martin, Guy Jerusalem, Sergio Venturini, Giuseppe Curigliano, Daniele Generali
CANCERS (2021)
Technical Challenges for CTC Implementation in Breast Cancer
Rocio Ramos-Medina, Sara Lopez-Tarruella, Maria Del Monte-Millan, Tatiana Massarrah, Miguel Martin
CANCERS (2021)
Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline BRCA1/2-Mutated Breast Cancer
Joanne L. Blum, A. Douglas Laird, Jennifer K. Litton, Hope S. Rugo, Johannes Ettl, Sara A. Hurvitz, Miguel Martin, Henri H. Roche, Kyung-Hun Lee, Annabel Goodwin, Ying Chen, Silvana Lanzalone, Jijumon Chelliserry, Akos Czibere, Julia F. Hopkins, Lee A. Albacker, Lida A. Mina
CLINICAL CANCER RESEARCH (2022)
How we treat HR-positive, HER2-negative early breast cancer
Sara Lopez-Tarruella, Isabel Echavarria, Yolanda Jerez, Blanca Herrero, Salvador Gamez, Miguel Martin
FUTURE ONCOLOGY (2022)
Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03)
Michael Gnant, Amylou C. Dueck, Sophie Frantal, Miguel Martin, Hal J. Burstein, Richard Greil, Peter Fox, Antonio C. Wolff, Arlene Chan, Eric P. Winer, Georg Pfeiler, Kathy D. Miller, Marco Colleoni, Jennifer M. Suga, Gabor Rubovsky, Judith M. Bliss, Ingrid A. Mayer, Christian F. Singer, Zbigniew Nowecki, Olwen Hahn, Jacqui Thomson, Norman Wolmark, Kepa Amillano, Hope S. Rugo, Guenther G. Steger, Blanca Hernando Fernandez de Aranguiz, Tufia C. Haddad, Antonia Perello, Meritxell Bellet, Hannes Fohler, Otto Metzger Filho, Anita Jallitsch-Halper, Kadine Solomon, Celine Schurmans, Kathy P. Theall, Dongrui R. Lu, Kathleen Tenner, Christian Fesl, Angela DeMichele, Erica L. Mayer
JOURNAL OF CLINICAL ONCOLOGY (2022)
HER2+Breast Cancer Escalation and De-Escalation Trial Design: Potential Role of Intrinsic Subtyping
Coralia Bueno Muino, Miguel Martin, Maria del Monte-Millan, Jose Angel Garcia-Saenz, Sara Lopez-Tarruella
CANCERS (2022)
Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study
Miguel Martin, Christoph Zielinski, Manuel Ruiz-Borrego, Eva Carrasco, Eva M. Ciruelos, Montserrat Munoz, Begona Bermejo, Mireia Margeli, Tibor Csoszi, Antonio Anton, Nicholas Turner, Maria Casas, Serafin Morales, Emilio Alba, Lourdes Calvo, Juan De La Haba-Rodriguez, Manuel Ramos, Laura Murillo, Ana Santaballa, Jose L. Alonso-Romero, Pedro Sanchez-Rovira, Massimo Corsaro, Xin Huang, Christiane Thallinger, Zsuzsanna Kahan, Miguel Gil-Gil
EUROPEAN JOURNAL OF CANCER (2022)
Clinical and Sociodemographic Determinants of Adherence to World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) Recommendations in Breast Cancer Survivors-Health-EpiGEICAM Study
Virginia Lope, Angel Guerrero-Zotano, Emma Ruiz-Moreno, Begona Bermejo, Silvia Antolin, Alvaro Montano, Jose Manuel Baena-Canada, Manuel Ramos Vazquez, Nerea Fernandez de Larrea-Baz, Jose Ignacio Chacon, Jose Angel Garcia-Saenz, Clara Olier, Montserrat Munoz, Antonio Anton, Pedro Sanchez Rovira, Angels Arcusa Lanza, Sonia Gonzalez, Amparo Oltra, Joan Brunet, Joaquin Gavila Gregori, Maria Teresa Martinez, Lourdes Calvo, Libertad Rosell, Susana Bezares, Roberto Pastor-Barriuso, Beatriz Perez-Gomez, Miguel Martin, Marina Pollan
CANCERS (2022)
Long-term outcomes of high-risk HR-positive and HER2-negative early breast cancer patients from GEICAM adjuvant studies and El alamo IV registry
Miguel Martin, Eva Carrasco, Alvaro Rodriguez-Lescure, Raquel Andres, Sonia Servitja, Antonio Anton, Manuel Ruiz-Borrego, Begona Bermejo, Angel Guerrero, Manuel Ramos, Ana Santaballa, Montserrat Munoz, Josefina Cruz, Sara Lopez-Tarruella, Jose I. I. Chacon, Isabel Alvarez, Purificacion Martinez, Juan J. Miralles, Oscar Polonio, Carlos Jara, David Aguiar-Bujanda
BREAST CANCER RESEARCH AND TREATMENT (2023)
Intermediate Molecular Phenotypes to Identify Genetic Markers of Anthracycline-Induced Cardiotoxicity Risk
Aurora Gomez-Vecino, Roberto Corchado-Cobos, Adrian Blanco-Gomez, Natalia Garcia-Sancha, Sonia Castillo-Lluva, Ana Martin-Garcia, Marina Mendiburu-Elicabe, Carlos Prieto, Sara Ruiz-Pinto, Guillermo Pita, Alejandro Velasco-Ruiz, Carmen Patino-Alonso, Purificacion Galindo-Villardon, Maria Linarejos Vera-Pedrosa, Jose Jalife, Jian-Hua Mao, Guillermo Macias de Plasencia, Andres Castellanos-Martin, Maria del Mar Saez-Freire, Susana Fraile-Martin, Telmo Rodrigues-Teixeira, Carmen Garcia-Macias, Julie Milena Galvis-Jimenez, Asuncion Garcia-Sanchez, Maria Isidoro-Garcia, Manuel Fuentes, Maria Begona Garcia-Cenador, Francisco Javier Garcia-Criado, Juan Luis Garcia-Hernandez, Maria Angeles Hernandez-Garcia, Juan Jesus Cruz-Hernandez, Cesar Augusto Rodriguez-Sanchez, Alejandro Martin Garcia-Sancho, Estefania Perez-Lopez, Antonio Perez-Martinez, Federico Gutierrez-Larraya, Antonio J. Carton, Jose Angel Garcia-Saenz, Ana Patino-Garcia, Miguel Martin, Teresa Alonso-Gordoa, Christof Vulsteke, Lieselot Croes, Sigrid Hatse, Thomas Van Brussel, Diether Lambrechts, Hans Wildiers, Hang Chang, Marina Holgado-Madruga, Anna Gonzalez-Neira, Pedro L. Sanchez, Jesu Perez Losada
CELLS (2023)
Ribociclib plus letrozole in patients with hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC): Expanded safety analysis of the phase IIIb CompLEEment-1 trial
Janice Lu, Paul Cottu, Miguel Martin, Claudio Zamagni, Aleix Prat, Stephen Chia, Guy Jerusalem, Senthil Rajappa, Constanta Timcheva, Lyudmila Zhukova, Katie Zhou, Jiwen Wu, Lakshmi Menon-Singh, Michelino De Laurentiis
CANCER RESEARCH (2021)